Tada Hayato, Kawashiri Masa-aki, Ikewaki Katsunori, Terao Yoshio, Noguchi Tohru, Nakanishi Chiaki, Tsuchida Masayuki, Takata Mutsuko, Miwa Kenji, Konno Tetsuo, Hayashi Kenshi, Nohara Atsushi, Inazu Akihiro, Kobayashi Junji, Mabuchi Hiroshi, Yamagishi Masakazu
Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Circ Cardiovasc Genet. 2012 Feb 1;5(1):35-41. doi: 10.1161/CIRCGENETICS.111.960948. Epub 2011 Dec 9.
Autosomal recessive hypercholesterolemia (ARH) exhibits different responsiveness to statins compared with that in homozygous familial hypercholesterolemia (FH). However, few data exist regarding lipoprotein metabolism of ARH. Therefore, we aimed to clarify lipoprotein metabolism, especially the remnant lipoprotein fractions of ARH before and after statin therapy.
We performed a lipoprotein kinetic study in an ARH patient and 7 normal control subjects, using stable isotope methodology (10 mg/kg of [(2)H(3)]-leucine). These studies were performed at baseline and after the 20 mg daily dose of atorvastatin. Tracer/tracee ratio of apolipoprotein B (apoB) was determined by gas chromatography/mass spectrometry and fractional catabolic rates (FCR) were determined by multicompartmental modeling, including remnant lipoprotein fractions. FCR of low-density lipoprotein (LDL) apoB of ARH was significantly lower than those of control subjects (0.109 versus 0.450±0.122 1/day). In contrast, the direct removal of very-low-density lipoprotein remnant was significantly greater in ARH than those in control subjects (47.5 versus 2±2%). Interestingly, FCR of LDL apoB in ARH dramatically increased to 0.464 1/day, accompanying reduction of LDL cholesterol levels from 8.63 to 4.22 mmol/L after treatment with atorvastatin of 20 mg/d for 3 months.
These results demonstrate that ARH exhibits decreased LDL clearance associated with decreased FCR of LDL apoB and increased clearance for very-low-density lipoprotein remnant. We suggest that increased clearance of remnant lipoprotein fractions could contribute to the great responsiveness to statins, providing new insights into the lipoprotein metabolism of ARH and the novel pharmacological target for LDLRAP1.
与纯合子家族性高胆固醇血症(FH)相比,常染色体隐性高胆固醇血症(ARH)对他汀类药物的反应性不同。然而,关于ARH脂蛋白代谢的数据较少。因此,我们旨在阐明脂蛋白代谢,尤其是他汀类药物治疗前后ARH的残余脂蛋白组分。
我们使用稳定同位素方法(10mg/kg的[(2)H(3)]-亮氨酸),在1例ARH患者和7名正常对照受试者中进行了脂蛋白动力学研究。这些研究在基线时以及每日服用20mg阿托伐他汀后进行。载脂蛋白B(apoB)的示踪剂/被示踪剂比率通过气相色谱/质谱法测定,分解代谢率(FCR)通过多室模型测定,包括残余脂蛋白组分。ARH的低密度脂蛋白(LDL)apoB的FCR显著低于对照受试者(0.109对0.450±0.122 1/天)。相反,ARH中极低密度脂蛋白残余物的直接清除率显著高于对照受试者(47.5对2±2%)。有趣的是,在接受20mg/d阿托伐他汀治疗3个月后,ARH中LDL apoB的FCR显著增加至0.464 1/天,同时LDL胆固醇水平从8.63mmol/L降至4.22mmol/L。
这些结果表明,ARH表现出LDL清除率降低,与LDL apoB的FCR降低相关,而极低密度脂蛋白残余物的清除率增加。我们认为,残余脂蛋白组分清除率的增加可能有助于对他汀类药物的高反应性,为ARH的脂蛋白代谢和LDLRAP1的新药理学靶点提供了新的见解。